Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa

Corbella, L; Boán, Jorge; Juan, Rafael San; Fernández‐Ruiz, Mario; Carretero, Octavio; Lora, David; Hernández-Jiménez, Pilar; Ruiz-Ruigómez, María; Rodríguez‐Goncer, Isabel; Silva, José Tiago; López‐Medrano, Francisco; Lizasoaín, Manuel; Villa, Jennifer; Teller, José Manuel Caro; Paz‐Artal, Estela

doi:10.1016/j.ijantimicag.2021.106517

Cited by 29 publications

(32 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In accordance with a retrospective cohort study conducted on MDR/XDR P. aeruginosa infection patients with CAZ/AVI therapy, it reported that clinical cure rate was 54.1% at 14-day, and all-cause mortality was 13.1% at 30-day, which was similar to the results of our study. 25 However, a previous multicenter study including MDR Gram-negative bacteria (GNB) (other than Carbapenem-Resistant Enterobacterales (CRE)) patients with CAZ/AVI therapy in Italy, reported the clinical cure rate of 87.8% in MDR-PA patients. 24 The discrepancy between previous studies and our study might be due to the distinct research population and different conditions.…”

Section: Discussionmentioning

confidence: 99%

Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients

Chen¹,

Liang²,

Ding³

et al. 2023

IDR

View full text Add to dashboard Cite

Background Experience of ceftazidime-avibactam (CAZ/AVI) for carbapenem-resistant Pseudomonas aeruginosa (CRPA) infection in recipients after lung transplantation (LT) is relatively limited. Methods A retrospective observational study was conducted on lung transplant recipients receiving CAZ/AVI therapy for CRPA infection. The primary outcomes were the 14-day and 30-day mortality. The secondary outcomes were clinical cure and microbiological cure. Results Among 183 LT recipients, a total of 15 recipients with CRPA infection who received CAZ/AVI therapy were enrolled in this study. The mean age of recipients was 54 years and 73.3% of recipients were male. The median time from infection onset to initiation of CAZ/AVI treatment was 4 days (IQR, 3–7) and the mean duration of CAZ/AVI therapy was 10 days. CAZ/AVI was mainly administered as monotherapy in LT recipients (80%). Among these eligible recipients, 14-day and 30-day mortality were 6.7% and 13.3%, respectively. The clinical cure and microbiological cure rates of CAZ/AVI therapy were 53.3% and 60%, respectively. Three recipients (20%) experienced recurrent infection. In addition, the mean lengths of ICU stay and hospital stay were 24 days and 35 days, respectively, among LT recipients. Conclusion CAZ/AVI may be an alternative and promising regimen for CRPA eradiation in lung transplant recipients.

show abstract

Section: Discussionmentioning

confidence: 99%

Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients

Chen¹,

Liang²,

Ding³

et al. 2023

IDR

View full text Add to dashboard Cite

show abstract

“…Resistance induction by ceftazidime-avibactam remains an issue of concern, with diminished outer membrane permeability and overexpression of efflux pumps or AmpC as underlying mechanisms. Whilst some studies have reported resistance ceftazidime-avibactam rates of 20%, resistance was not detected in other series [8]. Although AmpC derepression also increases MIC of ceftalozane-tazobactam, clinical resistance to this new combination requires an additional structural modification of AmpC, which could explain the lower development of resistance.…”

Section: Sirmentioning

confidence: 91%

Recurrent ventilator-associated pneumonia caused by “difficult to treat” resistance Pseudomonas aeruginosa

Rodríguez-Aguirregabiria¹,

Asensio-Martín²,

Nanwani-Nanwani³

2022

Rev Esp Quimioter

View full text Add to dashboard Cite

show abstract

“…In a recent Spanish retrospective cohort study, the clinical outcomes of 61 consecutive infection episodes mostly composed of pneumonia and BSIs and caused by MDR P. aeruginosa were reported. With CZA treatment (47.5% as a combination therapy), the clinical cure was achieved in 54.1% of the patients by day 14, and the 30-day all-cause mortality rate was 13.1% [ 147 ]. To date, no pathogen-directed RCT has been conducted for comparing CZA with the best available therapy (BAT) in CRE and CRPA infections.…”

Section: Novel Blblismentioning

confidence: 99%

The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations

Aslan

Akova

2022

Antibiotics

View full text Add to dashboard Cite

With the current crisis related to the emergence of carbapenem-resistant Gram-negative bacteria (CR-GNB), classical treatment approaches with so-called “old-fashion antibiotics” are generally unsatisfactory. Newly approved β-lactam/β-lactamase inhibitors (BLBLIs) should be considered as the first-line treatment options for carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA) infections. However, colistin can be prescribed for uncomplicated lower urinary tract infections caused by CR-GNB by relying on its pharmacokinetic and pharmacodynamic properties. Similarly, colistin can still be regarded as an alternative therapy for infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) until new and effective agents are approved. Using colistin in combination regimens (i.e., including at least two in vitro active agents) can be considered in CRAB infections, and CRE infections with high risk of mortality. In conclusion, new BLBLIs have largely replaced colistin for the treatment of CR-GNB infections. Nevertheless, colistin may be needed for the treatment of CRAB infections and in the setting where the new BLBLIs are currently unavailable. In addition, with the advent of rapid diagnostic methods and novel antimicrobials, the application of personalized medicine has gained significant importance in the treatment of CRE infections.

show abstract

Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa

Cited by 29 publications

References 46 publications

Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients

Ceftazidime/Avibactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosa Infection in Lung Transplant Recipients

Recurrent ventilator-associated pneumonia caused by “difficult to treat” resistance Pseudomonas aeruginosa

The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations

Contact Info

Product

Resources

About